Myocarditis as a trigger for the expression of biventricular arrhythmogenic cardiomyopathy in desmosomal gene mutation.

ICC criteria biventricular arrhythmogenic-cardiomyopathy gene expression myocarditis plakophilin-2 gene mutation sudden cardiac death

Journal

Echocardiography (Mount Kisco, N.Y.)
ISSN: 1540-8175
Titre abrégé: Echocardiography
Pays: United States
ID NLM: 8511187

Informations de publication

Date de publication:
10 2023
Historique:
revised: 16 07 2023
received: 24 06 2023
accepted: 20 07 2023
medline: 11 10 2023
pubmed: 11 8 2023
entrez: 10 8 2023
Statut: ppublish

Résumé

Arrhythmogenic-cardiomyopathy (ACM) is an inherited heart disease with right, left, or biventricular (BVACM) involvement based on EKG, imaging, family history, and genetic testing. We present a 64-year-old woman with prior myocarditis and diagnosis of BVACM 29 years later. We propose myocarditis as a promoter of gene expression of plakophilin-2 mutation.

Identifiants

pubmed: 37563622
doi: 10.1111/echo.15665
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1122-1126

Informations de copyright

© 2023 The Authors. Echocardiography published by Wiley Periodicals LLC.

Références

Corrado D, Perazzolo Marra M, Zorzi A, et al. Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol. 2020;319:106-114.
Corrado D, Zorzi A, Cipriani A, et al. Evolving diagnostic criteria for arrhythmogenic cardiomyopathy. J Am Heart Assoc. 2021;10:e021987. doi:10.1161/JAHA.121.021987
Towbin JA, McKenna WJ, Abrams DJ, et al. HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019;16:e373-e407.
te Riele AS, Tandri H, Bluemke DA. Arrhythmogenic right ventricular cardiomyopathy: cardiovascular magnetic resonance update. J Cardiovasc Magn Reson. 2014;16:50. doi:10.1186/s12968-014-0050-8
Dalal D, Molin LH, Piccini J, et al. Clinical features of arrhythmogenic right ventricular cardiomyopathy associated with mutations in plakophilin-2. Circulation. 2006;113:1641-1649.
Bosman LP, Te Riele ASJM. Arrhythmogenic right ventricular cardiomyopathy: a focused update on diagnosis and risk stratification. Heart. 2022;108:90-97.
Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43:3997-4126.
Saguner AM, Brunckhorst C, Duru F. Arrhythmogenic ventricular cardiomyopathy:a paradigm shift from right to biventricular disease. World J Cardiol. 2014;26:154-174.
Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533-1541.
Bosman LP, Sammani A, James CA, et al. Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: a systematic review and metanalysis. Heart Rhythm. 2018;15:1097-1107.
Cadrin-Tourigny J, Bosman LS, Wang W, et al. Sudden cardiac death prediction in arrhythmogenic right ventricular cardiomyopathy: a multinational collaboration. Circ Arrhythm Electrophysiol. 2021;14(1):e008509.
Seferovic PM, Polovina M, Bauersachs J, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:553-576.
Bariani R, Rigato I, Cipriani A, et al. Myocarditis-like episodes in patients with arrhythmogenic cardiomyopathy: a systematic review on the so-called hot-phase of the disease. Biomolecules. 2022;19:1324. doi:10.3390/biom12091324
Pilichou K, Remme CA, Basso C, et al. Myocyte necrosis underlies progressive myocardial dystrophy in mouse Dsg2-related arrhythmogenic right ventricular cardiomyopathy. J Exp Med. 2009;206:1787-1802.
Chatterjee D, Fatah M, Akdis D, et al. An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis. Eur Heart J. 2018;39:3932-3944.

Auteurs

Nicholas Johnson (N)

Department of Cardiology & Translational Cardiovascular Research Group, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK.

Matthew Ginks (M)

Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Vanessa M Ferreira (VM)

Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, England, UK.

Attila Kardos (A)

Department of Cardiology & Translational Cardiovascular Research Group, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK.
Faculty of Medicine and Health Sciences, University of Buckingham, Buckingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH